Juventas Therapeutics is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials. Investors include Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received nondilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.

Patents 56show all

  • 29
    A61K - Preparations for medical, dental, or toilet purposes
  • 22
    C07K - Peptides
  • 18
    A61G - Transport or accomodation for patients
  • 6
    A61M - Devices for introducing media into, or onto, the body
  • 6
    C12N - Microorganisms or enzymes
  • 2
    A61B - Diagnosis
  • 1
    A61F - Filters implantable into blood vessels

Clinical Trials 7show all

4Phase 21Phase 11Phase 1/Phase 2

SEC Filings show all


6
D

Contact Information

3615 Superior Avenue Suite 4403C
Cleveland, OH 44114
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$48,716,00011-502015-05-12Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2008-10-23$7,716,000Series AEarly Stage Partners, Triathlon Medical Venture Partners
2012-07-16$22,200,000Series BTriathlon Medical Venture Partners, New Science VenturesFletcher Spaght, Inc., Early Stage Partners, Takeda Ventures, North Coast Ventures, Venture Investors, Reservoir Venture Partners
2008-09-30$300,000SeedJumpStart
2013-11-20$5,000,000Series Unknown
2015-05-12$13,500,000Series BPOSCO Venture Capital, Green Cross

SEC Form D Funding Events

DateOfferedSoldType
2013-11-20$5,000,000$5,000,000Equity, Option to Acquire, Other
2012-08-08$22,060,000$22,060,000Equity
2012-02-03$20,000,000$12,000,000Equity
2008-10-14Unknown Unknown Other (Paper Filing)

Key Executives

  • Rahul Aras
    Executive Officer, Director
  • George Emont
    Director
  • Somu Subramaniam
    Director
  • Matt Pollman
    Director
  • Marc Penn
    Director
  • Roger Newton
    Director
  • Linda Tufts
    Director
  • George Arida
    Director
  • Suzette Dutch
    Director
  • Matthew Pollman
    Director